Evidence map›Paper›PMID 28948187›Full record

ArticleMolecular therapy. Methods & clinical development2017

Profiling the Targets of Protective CD8

Joseph T Bruder, Ping Chen, Greg Ekberg, Emily C Smith, Christopher A Lazarski, Bennett A Myers, Jessica Bolton, Martha Sedegah, Eileen Villasante, Thomas L Richie and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Joseph T BruderGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Ping ChenGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Greg EkbergGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Emily C SmithMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Christopher A LazarskiGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Bennett A MyersGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Jessica BoltonMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Martha SedegahMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Eileen VillasanteMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Thomas L RichieMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
C Richter KingGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
Joao C AguiarMalaria Department, Naval Medical Research Center (NMRC), 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Denise L DoolanAustralian Institute of Tropical Health and Medicine, James Cook University, McGregor Road, Cairns, QLD 4870, Australia.
Douglas E BroughGenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA.
GenVec · USNaval Medical Research Command · USAustralian Institute of Tropical Health and Medicine · AUHenry M. Jackson Foundation · US

Funding

High Throughput Genomics Screening for Malaria Antigen DiscoveryR43AI084269 · NIAID · GENVEC, INC. · PI BRUDER, JOSEPH T · 2009 to 2010
$600k
Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine DevelopmentR43AI100467 · NIAID · GENVEC, INC. · PI BROUGH, DOUGLAS E. · 2012 to 2013
$600k
NIAID NIH HHS R43 AI084269NIAID NIH HHS R43 AI100467
6 · The paper itself

Abstract

T cells are critical effectors of host immunity that target intracellular pathogens, such as the causative agents of HIV, tuberculosis, and malaria. The development of vaccines that induce effective cell-mediated immunity against such pathogens has proved challenging; for tuberculosis and malaria, many of the antigens targeted by protective T cells are not known. Here, we report a novel approach for screening large numbers of antigens as potential targets of T cells. Malaria provides an excellent model to test this antigen discovery platform because T cells are critical mediators of protection following immunization with live sporozoite vaccines and the specific antigen targets are unknown. We generated an adenovirus array by cloning 312 highly expressed pre-erythrocytic

Indexed as

adenovirusantigenantigen discoverymalariascreenT cellvaccinevectorviral vector

Identifiers

PMID28948187
PMCPMC5602877
OpenAlexW2746973134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.